HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI

被引：19

作者：

Mok, Tony ^{[1
,2
]}

Jaenne, Pasi A. ^{[3
]}

Nishio, Makoto ^{[4
]}

Novello, Silvia ^{[5
]}

Reck, Martin ^{[6
]}

Steuer, Conor ^{[7
]}

Wu, Yi-Long ^{[8
]}

Fougeray, Ronan ^{[9
]}

Fan, Pang-Dian ^{[9
]}

Meng, Jie ^{[9
]}

Sternberg, David W. ^{[9
]}

Esker, Stephen ^{[9
]}

Yu, Helena A. ^{[10
]}

机构：

[1] State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China

[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China

[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02215 USA

[4] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Thorac Med Oncol, Tokyo 1358550, Japan

[5] Univ Turin, San Luigi Hosp Orbassano, Oncol Dept, I-10124 Turin, Italy

[6] LungenClin, Airway Res Ctr North, German Ctr Lung Res, Dept Thorac Oncol, D-22927 Grosshansdorf, Germany

[7] Emory Univ, Winship Canc Inst, Hematol & Med Oncol, Atlanta, GA 30322 USA

[8] Guangdong Prov Peoples Hosp, Lung Canc Inst, Guangzhou 510317, Peoples R China

[9] Daiichi Sankyo Inc, Oncol Clin Dev, Basking Ridge, NJ 07920 USA

[10] Mem Sloan Kettering Canc Ctr, Med Oncol, Dept Med, New York, NY 10065 USA

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 15期

关键词：

antibody-drug conjugate; EGFR-activating mutation; HER3-DXd; non-small-cell lung cancer; patritumab deruxtecan; CELL LUNG-CANCER; OSIMERTINIB; INHIBITOR; GEFITINIB; CARBOPLATIN; PACLITAXEL; RESISTANCE; EFFICACY; DS-8201A;

D O I：

10.2217/fon-2023-0602

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

After disease progression on EGFR tyrosine kinase inhibitor (TKI) therapy, patients with EGFR-mutated NSCLC who are then treated with platinum-based chemotherapy (PBC) obtain only limited clinical benefit with transient responses. Therapies with greater efficacy and tolerable safety profiles are needed in this setting. The receptor tyrosine kinase HER3 is widely expressed in NSCLC, and increased expression is associated with poor treatment outcomes. In the U31402-A-U102 phase I trial, HER3-DXd showed promising antitumor activity with manageable safety in heavily pre-treated patients with EGFR-mutated NSCLC across a range of tumor HER3 expression levels and EGFR TKI resistance mechanisms. HERTHENA-Lung02 is the first phase III trial to evaluate the safety and efficacy of HER3-DXd versus PBC in patients with progression on a third-generation EGFR TKI.

引用

页码：969 / 980

页数：12

共 50 条

[21] Pathological and Molecular Alterations after First and Second Generation EGFR-TKI Therapy in Patients with EGFR-Mutated Lung Adenocarcinomas
Uruga, H.
Fujii, T.
Yamamoto, G.
Moriguchi, S.
Takahashi, Y.
Ogawa, K.
Murase, R.
Mochizuki, S.
Hanada, S.
Takaya, H.
Miyamoto, A.
Morokawa, N.
Kishi, K.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2249 - S2249
[22] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Cheng, Ying
He, Yong
Li, Wei
Zhang, He-long
Zhou, Qing
Wang, Buhai
Liu, Chunling
Walding, Andrew
Saggese, Matilde
Huang, Xiangning
Fan, Minhao
Wang, Jia
Ramalingam, Suresh S.
TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
[23] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Ying Cheng
Yong He
Wei Li
He-long Zhang
Qing Zhou
Buhai Wang
Chunling Liu
Andrew Walding
Matilde Saggese
Xiangning Huang
Minhao Fan
Jia Wang
Suresh S. Ramalingam
Targeted Oncology, 2021, 16 : 165 - 176
[24] Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Yu, H. A.
Cantero, F.
Kim, B.
Lee, M.
Wu, E.
Sternberg, D. W.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1092 - S1093
[25] Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study
Sun, R. -L.
Liao, Y. -T.
Shen, C. -I.
Chiang, C. -L.
Tseng, Y. -H.
Hsiao, T. -H.
Chao, H. -S.
Luo, Y. -H.
Chen, Y. -M.
Huang, H. -C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S645 - S645
[26] A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)
Wehler, T.
Hirsh, V.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1043 - S1043
[27] Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC
Wakelee, Heather
Goldman, Jonathan W.
Gadgeel, Shirish
Camidge, David R.
Reckamp, Karen L.
Ou, Sai-Hong I.
Yu, Helena A.
Solomon, Benjamin
Liu, Stephen V.
Perol, Maurice
Dupuis, Nicholas F.
Nickel, Alex
Karlovich, Chris
Raponi, Mitch
Yurasov, Sergey
Litten, Jason
Despain, Darrin
Soria, Jean-Charles
Sequist, Lecia
Carbonell, David
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S311 - S312
[28] Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
Yu, H. A.
Baik, C.
Kim, D. -W.
Johnson, M. L.
Hayashi, H.
Nishio, M.
Yang, J. C. -H.
Su, W. -C.
Gold, K. A.
Koczywas, M.
Smit, E. F.
Steuer, C. E.
Felip, E.
Murakami, H.
Kim, S. -W.
Su, X.
Sato, S.
Fan, P. -D.
Fujimura, M.
Tanaka, Y.
Patel, P.
Sternberg, D. W.
Sellami, D.
Jaenne, P. A.
ANNALS OF ONCOLOGY, 2024, 35 (05) : 437 - 447
[29] A Phase III Study of Rilertinib Versus Gefitinib as FirstLine Therapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC
Zhou, C.
Xiong, A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S11 - S11
[30] CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Zhou, Q.
Wu, Y-L.
Cheng, Y.
Liu, Y.
Chen, G.
Cui, J.
Yang, N.
Song, Y.
Li, X-L.
Lu, S.
Zhou, J.
Ma, Z.
Yu, S-Y.
Huang, C.
Shu, Y.
ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →